NES
ALNY icon

New England Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

New England Securities’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$4K Hold
40
– – ﹤0.01% 1309
2014
Q3 		$3K Buy
+40
New +$2.58K ﹤0.01% 1377

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

New England Securities's ALNY Position: Q4 2014 in Review

New England Securities held its Alnylam Pharmaceuticals (ALNY) position steady in Q4 2014 at 40 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1309.

New England Securities first reported a position in ALNY in Q3 2014 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold ALNY as of Q4 2014.

  • New England Securities held 40 shares of Alnylam Pharmaceuticals worth $4K as of Q4 2014.
  • New England Securities left its Alnylam Pharmaceuticals share count unchanged in Q4 2014.
  • Alnylam Pharmaceuticals made up ﹤0.01% of New England Securities's portfolio in Q4 2014, its #1309 holding.
  • New England Securities first reported a position in Alnylam Pharmaceuticals in Q3 2014 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2014.

Based on New England Securities's 13F filing for Q4 2014, filed 26 Jan 2015.